T.L. Silveira

T.L. Silveira

Auto-generated profile, based on publicly available information

T.L. Silveira

Universidade Federal de Minas Gerais, Brazil

Research Focus & Metrics

Representative Publications

View All Publications
1 March 2022 in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
Verified
Journal Article
Open access
FNF.C. Nunes
F.C. Nunes
ABA.C. Bertagnolli
A.C. Bertagnolli
GLG.E. Lavalle
G.E. Lavalle
TST.L. Silveira
T.L. Silveira
DBDébora Balabram
Débora Balabram
Geovanni Dantas CassaliGeovanni Dantas Cassali
Geovanni Dantas Cassali
Canine malignant mammary neoplasms (CMMN) exhibit behavioral variability with the patient survival time depending on several prognostic factors. In the present study, 134 CMMN were selected and different immunophenotypes and their associations with clinical and pathological parameters were identified. The tumors were classified as follows: 46% of luminal B HER2-, 34% of luminal A, 13% of triple-negative, and 7% of luminal B HER2+. Shorter specific survival time were associated with larger tumor sizes (>3.0 cm, HR=1.94; P=0.0209), lymph node metastasis or distant metastasis (HR= 2.82; P <.0001), more aggressive histological types (HR= 7.15, P<0.0001), higher histological grades (HR= 12.97 P=0.011), angiolymphatic invasion (HR=4.68, P<0.0001) and luminal B HER2 - (HR= 3.27, P<0.0001) and luminal B HER2 + (HR= 7.14 P<0.0001) immunophenotypes. In patients with lymph nodal metastasis, shorter survival times were associated with luminal immunophenotype B HER2 + (P=0.003). However, in patients without metastasis, an increased risk of death was associated with the aggressive histological type. In conclusion, the classification in our study allowed us to identify subtypes with different prognoses in canine malignant mammary tumors. Factors such as clinical stage, histological type, luminal B HER2+ subtype, and angiolymphatic invasion were the most important prognostic factors.